Editor-in-Chief Hatice Kübra Elçioğlu Vice Editors Levent Kabasakal Esra Tatar Online ISSN 2630-6344 Publisher Marmara University Frequency Bimonthly (Six issues / year) Abbreviation J.Res.Pharm. Former Name Marmara Pharmaceutical Journal
Journal of Research in Pharmacy 2022 , Vol 26 , Issue 5
Therapeutic Drug Monitoring of Ticagrelor in Jordanian Patients. Development of Physiologically-Based Pharmacokinetic (PBPK) Model and Validation of Class IV Drugs of Salivary Excretion Classification System (SECS)
Mohammed KHALIL1,Akram AL-SALEH2,Hana MAKHAMREH2,Rabab TAYEM3,Mohammad ABUFARAH3,Abdullah ZUBI3,Omaimah NAJIB4,Mohammad BADER4,Naji NAJIB4,Suliman ALFAYOUMI1,Nasir IDKAIDEK1
1Faculty of Pharmacy, University of Petra, Amman, Jordan
2Jordan University Hospital, Amman, Jordan
3ACDIMA Biocenter, Amman, Jordan
4IPRC, Amman, Jordan
5Current address:865 Rainier Ave N Ste C102, Renton, WA 98057, USA
DOI : 10.29228/jrp.234 Ticagrelor is an orally administered antiplatelet agent that has been approved for the reduction of cardiovascular risk in patients with history of cardiovascular disease. However, Ticagrelor can also cause adverse effects, including dyspnea. Ticagrelor plasma and saliva concentrations of 63 Jordanian patients were measured using a sensitive LCMS/MS method. Ticagrelor was not excreted in saliva as it corresponds to the Class IV salivary excretion classification system. The correlation between plasma ticagrelor concentrations and the occurrence of dyspnea was examined to establish a therapeutic window for plasma ticagrelor. A physiologically-based pharmacokinetic (PBPK) model of ticagrelor was built and validated using previously- published plasma data. The validated model was then used to predict the factors affecting ticagrelor plasma concentrations. A loading dose of 135 mg (1.5 tablet) instead of 2 tablets has been suggested to maintain its therapeutic effect and avoid dyspnea. Keywords : Ticagrelor; pharmacokinetics; SECS; TDM; Gastroplus; PBPK
Marmara University